FOLFOX4

ApprovedSmall molecule

Eli Lilly

FOLFOX4 is one of 191 small molecule programs targeting Adenocarcinoma. It is currently in Approved.

Indications

Total Trials

Active Trials

190

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenocarcinomaActive, not recruiting

Liver CancerActive, not recruiting

Rectum CancerActive, not recruiting

Rectal CarcinomaActive, not recruiting

Colorectal CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

AdenocarcinomaPhase 2

Active, not recruiting

Liver CancerPhase 1

Active, not recruiting

Rectum CancerPhase 1

Active, not recruiting

Rectal CarcinomaPhase 2

Active, not recruiting

Colorectal CancerApproved

Active, not recruiting

Hepatocellular CarcinomaPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

949 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

FOLFOX4

Eli Lilly

Approved

1 2

Eylea

Regeneron

Preclinical

5 3

Emend IV

PORTRAZZA

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 6

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 7

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Andriol

AAuxilium

Preclinical

1 9

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 10

Vascepa

AAmarin Pharma Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

N/ARecruiting

Hepatocellular Carcinoma

NCT06893887

Q1 2029

Phase 1Recruiting

Rectum Cancer

NCT05912075

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma3 trials

Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma

Recruiting·NNanjing Tianyinshan Hospital·N/A·NCT06893887·300 enrolled

Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma

Withdrawn·GGuangxi Medical University·Phase 2/3·NCT02534337

Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma

Withdrawn·GGuangxi Medical University·Phase 2/3·NCT02527772

Chemotherapy2 trials

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03092895·157 enrolled

Chemotherapy Combined With CIK Treating Colon Cancer

Completed·UUnknown Sponsor·Phase 4·NCT03084809·46 enrolled

Adenocarcinoma1 trial

Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum

Terminated·UUniversity of Wisconsin, Madison·Phase 2·NCT00580073·6 enrolled

Rectal Carcinoma1 trial

Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma (COLORE)

Completed·IIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS·Phase 2·NCT02000050·52 enrolled

Rectum Cancer1 trial

Preoperative Radiotherapy And ASTX660 in Rectum Cancer

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1·NCT05912075·78 enrolled

4 more indications

PD-1 Inhibitor1 trial

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT03605706·396 enrolled

HCC1 trial

HR Combined With FOLFOX4 for HCC With PVTT

Unknown status·SSun Yat-sen University·Phase 2·NCT02452853·51 enrolled

Liver Cancer1 trial

A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02069041·8 enrolled

Colorectal Cancer1 trial

Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer

Unknown status·FFudan University·Phase 4·NCT00874406·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for FOLFOX4. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FOLFOX4 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FOLFOX4. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Eli Lilly

FOLFOX4

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q1 2029

Trials by Indication[1]

Hepatocellular Carcinoma3 trials

Chemotherapy2 trials

Adenocarcinoma1 trial

Rectal Carcinoma1 trial

Rectum Cancer1 trial

PD-1 Inhibitor1 trial

HCC1 trial

Liver Cancer1 trial

Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News